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Results: The main result was the reduction in primary and 
nodal volumes due to better definition of lung mass and 
nearby lung Collapse , the latter could be easily defined in 14 
cases on the DW-MRI vs. 7 cases only by CT scans (P=0.016). 
Median GTV total (sum of 1ry and nodal GTV), on MRI 
Diffusion compared to that on the CT scan was 354 and 386 
cm3 respectively (P= 0.009). In 15 cases, a mean decrease in 
the GTV total of 34% ±56% (median, 9%; range, 0.2- 32.5%) by 
using DW-MRI. only in three other cases a mean increase in 
the GTV total of 12.7% ±14.9% (median, 9.7%; range, 0.4- 
221%). was found. The median PTVs on the CT scans vs. the 
MRI Diffusion were 1623 (range, 493–2965 cm3) & 1419 
(range, 542–3158 cm3) respectively which was statistically 
non significant (P= 0.391).  
 
Conclusion: This pilot prospective study concluded that DW-
MRI as a functional image can aid in proper definition and 
delineation of the target volumes after fusion of DWI and the 
CT images . GTV Total decreased in most cases due to 
exclusion of collapse, consolidation, reactionary and 
inflammatory LN, however GTV total was increased in 3/20 
patients due to better nodal detection and better 
visualization of borders adjacent to the mediastinum and 
chest wall. DW MRI could be a future good tool for proper 
staging and guidance of radiotherapy in NSCLC cases 
indicated for chemo/radiation. 
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Purpose or Objective: Purpose: The aim of this work was to 
compare the patterns of NSCLC relapses after combined 
modality therapy with postoperative hypofractionated and 
conventionally fractionated radiotherapy and after sugery 
 
Material and Methods: Material/methods. We treated 528 
patients between January 1990 and January 2014 (men – 445, 
women – 83) aged 27-78 years (median age 59) with 
morphologically proven NSCLC (adenocarcinoma - 161, 
squamous cell cancer– 289, other types – 70 patients); stage 
I-126, stage II - 117, III - 111. All patients were operated: 
pnevmonectomy -180, lobe/belobectomy – 304, 
segmentectomy – 30, wedge resection -11. 227 patients 
received neoadjuvant or adjuvant platinum-based 
chemotherapy. Three groups were retrospectively analyzed: 
group I - 174 patients without postoperative radiotherapy 
(PORT), group II - 180 patients with postoperative 
hypofractionated radiotherapy with daily dose 3Gy up to the 
total dose 36Gy-39Gy (EQD2=43-47Gy, α/β=3) and group III - 
174 patients with postoperative radiotherapy with daily dose 
2Gy up to the total dose 44Gy. Bronchial stump, involved 
regional lymphatic nodes and uninvolved groups (2R, 2L, 3a, 
3p, 4R, 4L, 5, 6, 7 according to IASLC classification) were 
included in the CTV. The groups were comparable in the 
following parameters: age, ECOG status, stage, T- and N - 
classification and the proportion of the patients treated with 
chemotherapy. The duration of the follow-up was 0,33-16,0 
years, median - 2,25 years. The relapses were classified as 
local (in bronchial stump), regional, or distant. In the cases 
of mixt relapses (local ± regional ±distant) they were 
included in each category. 
 
Results: Results. 263(49,8%) patients relapsed: 231 (43,8%) 
had distant metastases, local relapse – 51 (9,7%), regional 
relapse – 54 (10,2%). The pattern of the relapses in each 
group is presented in the table. 
 
 
 
Conclusion: Conclusion. Hypofractionated postoperative 
radiotherapy (daily dose 3Gy, total dose 36-39Gy) 
significantly decrease the probability of local and regional 
relapse in NSCLC patients as well as the total number of the 
relapses without any effect with regard to distant 
metastases. Hypofractionated PORT is equally effective as 
conventional PORT (daily dose 2Gy, total dose 44Gy) with 
regard to locoregional control but has the clear logistical 
advantage. 
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Purpose or Objective: Increasing the radiotherapy dose can 
result in improved local control for non-small-cell lung cancer 
(NSCLC) and can thereby improve survival. This can be 
compromised by accelerated repopulation of tumour cells 
during radiotherapy. Accelerated hypofractionated 
radiotherapy (AHRT) can expose tumors to a high dose of 
radiation in a short period of time. We have employed this 
approach in two groups of NSCLC: 1) early stage NSCLC 
patients who cannot tolerate the SABR treatment process (for 
example, extended periods in the treatment position) or who 
cannot travel to a centre with SABR; and 2) stage III NSCLC 
unfit for concurrent chemotheraphy.  
This study was performed to evaluate the feasibility of 
utilizing AHRT for these patients. 
 
Material and Methods: 76 patients (46 stage I-II and 30 local 
advanced NSCLC) were included. All patients had FDG-PET 
scan. Only the primary tumour and the positive mediastinal 
areas on the pre-treatmement FDG-PET scan were irradiated. 
Mean age was 77.9 ± 7.9 years. The performance status (PS) 
was > 2 in 50% of cases. The radiotherapy was delivered in 
2.75 Gy fractions, once daily to a total dose of 66 Gy (BED10: 
84 Gy). Sequential chemotheraphy (mainly platinum and 
vinorelbine) was administered in 95% of stage III patients. 
Acute/late toxicity was evaluated using the RTOG criteria. 
 
Results: After a mean follow-up of 2 years, the median 
overall survival (OS) and cause specific survival (CSS) were 23 
and 54 months, respectively. On multivariate Cox regression 
analysis, PS >2 was an independent risk factor for OS 
(p<0.0001) and CSS (p<0.0001). The major acute adverse 
reactions were grade 2 dermitis (18%), grade 2 esophagitis 
(10%) and grade 1 pneumonitis (26%). There were 34 patients 
with grade 1 late pneumonitis. 
